Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.

Slides:



Advertisements
Similar presentations
Multicenter database of clinical course of CKD patients Internal Medicine Jang Hye Ryoun.
Advertisements

IRMA TRUpoint Creatinine Cartridge Field Launch
Girish Singhania N Engl J Med 2012 Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome.
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
THE IMPORTANCE OF PUBLISHING NEGATIVE FINDINGS Rolofylline, an Adenosine A1 – Receptor Antagonist, in Acute Heart Failure Barry M. Massie et al The New.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Chronic Kidney Disease and Dialysis Patient Care – What the Generalist Should Know Stephen R. Ash, MD, FACP Clarian Arnett Health Director of Dialysis,
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
Journal Club Rakesh Latchamsetty October 5, 2007.
SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.
REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
Chapter 2: Healthy People A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
Chapter 5: Acute Kidney Injury 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
臨床藥事照護 年 09 月其他之用藥建議 疑問藥物問題內容後續追蹤 Actein qid 2 包非正常使用 dose FOR CKD 病人的腎臟 保護 2 文獻資料資料來源 Prophylactic oral administration of the antioxidant.
Diabetes and Kidney. Diabetic Kidney Normal Kidney.
Acetylcysteine for the prevention of Contrast- induced nephropaThy (ACT) Trial: The ACT Trial Investigators Presenter: Otavio Berwanger (MD; PhD) Chair.
Radiocontrast Nephropathy Jason S. Finkelstein, M.D. Tulane University HSC Division of Cardiology 3/2/04.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Monthly Journal article review: Vimmi Kang PGY 2
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Hexabrix Key Clinical Review Liss, 2006 Mid-Year Sales Meeting Bloomington, IN July 13 th – 17 th.
Chapter 5: Acute Kidney Injury 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 2: Healthy People 2020.
Prevention of Serious Adverse Outcomes Following Angiography (PRESERVE) Trial Steven D. Weisbord MD, MSc.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.
Retrospective Monocentric 10-Year Analysis Of Sepsis-Associated Acute Kidney Injury: Impact On Outcome, Dialysis Dose And Residual Renal Function 1 Vincenzo.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Readmissions After Carotid Artery Revascularization.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
An AKI project for critically ill cancer patients
What should the Systolic BP treatment goal be in patients with CKD?
Nephrology Journal Club The SPRINT Trial Parker Gregg
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The SPRINT Research Group
Early high-dose Rosuvastatin for
The Relationship between Postoperative Serum Albumin Level and Organ Dysfunction after Liver Transplantation. Results No differences were found between.
Patient populations by study group figure 10
Clinical Research at the VA
2017 Annual Data Report Healthy People 2020.
VA Cooperative Studies Program Trial # 578
Volume 1: Chronic Kidney Disease Chapter 5: Acute Kidney Injury
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention.
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Hexabrix Key Clinical Review Mehran, 2009
2018 Annual Data Report Volume 3: Healthy People 2020
2018 Annual Data Report Volume 1: Chronic Kidney Disease
European Heart Association Journal 2007 April
Monthly Journal article review: Vimmi Kang PGY 2
Hexabrix Key Clinical Review Le Feuvre, 2006
Update in Nephrology 2013 Does AKI lead to ESRD?
Presentation transcript:

Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I

Contrast and renal dysfunction Contrast nephropathy is 3 rd leading cause of hospital acquired AKI Pathogenesis not clear – toxic and ischemic injury to renal tubular cells (intrarenal vasoconstriction, medullary hypoxia, direct tubular cell death); length of exposure (lower the GFR = longer time period of excretion) serum Cr levels > 4.5 mg/dl - CN approaches 100% for diabetic patients and 60% for non-diabetic patients serum Cr levels > 4.5 mg/dl - CN approaches 100% for diabetic patients and 60% for non-diabetic patients

Prophylaxis to CIN and study hypothesis fluid supplements, low-osmolality contrast, a double dose of N-acetylcysteine – general population and mild CKD fluid supplements, low-osmolality contrast, a double dose of N-acetylcysteine – general population and mild CKD contrast media can be effectively removed from the blood of patients with chronic renal failure by hemodialysis Hypothesis – prophylactic hemodialysis would prevent CN in pts with advanced renal failure undergoing coronary procedures Hypothesis – prophylactic hemodialysis would prevent CN in pts with advanced renal failure undergoing coronary procedures

Study design and methods Prospective, RCT Participants – 8/2003 – 6/2006 Veterans General hospital in Taiwan inclusion criteria- older than 20 yo, referred for coronary angiography, and “stable” Cr >3.5 mg/dL (change of Cr 3.5 mg/dL (change of Cr <0.5mg/dL in past month) exclusion - contrast medium within the previous 7 days, treatment with metformin or NSAIDs drugs within the previous 48 h, newly diagnosed unstable diabetes, renal transplantation, and ESRD necessitating chronic dialysis.

Methods cont. Procedures – all participants given 1mL/kg/hr x 6 hrs before and 12 hrs after exposure to contrast (non-ionic iohexol)– then randomized to receive HD (experimental gr) or no dialysis (control gr) Procedures – all participants given 1mL/kg/hr x 6 hrs before and 12 hrs after exposure to contrast (non-ionic iohexol)– then randomized to receive HD (experimental gr) or no dialysis (control gr) Follow up – CrCl measured before and on 4 th day after angiography; additional Cr drawn if pt had incr in Cr > 25% from BL (AKI) every other day until dialysis started or renal function recovered and at discharge in all patients who did not need dialysis. Follow up – CrCl measured before and on 4 th day after angiography; additional Cr drawn if pt had incr in Cr > 25% from BL (AKI) every other day until dialysis started or renal function recovered and at discharge in all patients who did not need dialysis. Primary endpoint: change in CrCl between baseline and the fourth day; Secondary end points were the differences in Cr levels on the fourth day from baseline, peak Cr level during hospitalization, and Cr level at discharge between groups Primary endpoint: change in CrCl between baseline and the fourth day; Secondary end points were the differences in Cr levels on the fourth day from baseline, peak Cr level during hospitalization, and Cr level at discharge between groups

RESULTS 3,724 patients screened – 318 with CKD - Eighty-eight patients had ESRD patients had Cr 3.5mg/dl – 18 patients refused to enter the study - and 90 were enrolled and of these 42 were assigned to experimental gr and 40 to control group 3,724 patients screened – 318 with CKD - Eighty-eight patients had ESRD patients had Cr 3.5mg/dl – 18 patients refused to enter the study - and 90 were enrolled and of these 42 were assigned to experimental gr and 40 to control group 2 groups were similar with respect to demographic and baseline clinical characteristics. Among the patients in the dialysis group, dialysis was initiated at an interval of 81+/-32 min, ranging from 45 to 180 min, after exposure to the contrast medium 2 groups were similar with respect to demographic and baseline clinical characteristics. Among the patients in the dialysis group, dialysis was initiated at an interval of 81+/-32 min, ranging from 45 to 180 min, after exposure to the contrast medium

Discussion Patients with chronic renal failure are prone to atherosclerotic cardiovascular diseases, and renal dysfunction accounts for the greatest risk factor in developing CN after CAG. Patients with chronic renal failure are prone to atherosclerotic cardiovascular diseases, and renal dysfunction accounts for the greatest risk factor in developing CN after CAG. Once CN occurred, 36% to 60% of these high-risk patients required emergent dialysis, and the hospital stay was prolonged to an average of 17 days

Discussion Primary endpoint - change in CrCl between baseline and the fourth day: The baseline CrCl was similar in the dialysis (13.2 ml/min/1.73 m 2 ) and control (12.6 ml/min/1.73 m 2 ) groups; however, the CrCl on the fourth day after coronary angiography in the dialysis group was significantly higher than that in the control group Secondary end points - differences in Cr levels on the fourth day from baseline, peak Cr level during hospitalization, and Cr level at discharge between groups Significant differences between 2 groups in Cr levels on day 4 and peak; no significant difference in Cr levels at discharge between 2 groups

Discussion Length of hospital stay in dialysis vs control was 6 +/- 3 VS 13 +/- 18 (p = 0.017) Patients with kidney disease make up just 1% of the Medicare population, but account for nearly 10% of all Medicare costs. They average 1.8 hospitalizations per year, totaling 12 days. On average, renal patients stay 0.7 days longer and cost $7,975 more per hospital admission when compared to all Medicare patients The renal function of patients in the dialysis group was better preserved over the whole course after CAG compared with the control group. The renal function of patients in the dialysis group was better preserved over the whole course after CAG compared with the control group. Findings suggest that prophylactic hemodialysis in patients with advanced chronic renal failure undergoing coronary angiography reduces the intensity of acute renal deterioration due to contrast medium exposure, shortens hospital stay, and improves renal outcome. Findings suggest that prophylactic hemodialysis in patients with advanced chronic renal failure undergoing coronary angiography reduces the intensity of acute renal deterioration due to contrast medium exposure, shortens hospital stay, and improves renal outcome.